For Blue RX members, Pacific Blue Cross will align with PharmaCare to modify the criteria for initial coverage of the following anticoagulants so that a prior trial of warfarin therapy and subsequent lab tests will no longer be required. Affected drugs include:
Rivaroxaban (Xarelto)
Apixaban (Eliquis)
Edoxaban (Lixiana)
Dabigatran (Pradaxa)
For further details, please refer to BC PharmaCare Newsletter Edition 20-006: https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/newsletters/news20-006.pdf